Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MTTP | P55157 | 2/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6254182 | 0.85 | MTTP (0.58) | L3MBTL1MTTPGPR88 | |
| SCHEMBL6813773 | 0.81 | F2 (0.47) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL6254177 | 0.80 | L3MBTL1 (0.45) | NPC1RAB9AKMT2AL3MBTL1MTTP | |
| SCHEMBL6255765 | 0.77 | MTTP (0.58) | NPC1RAB9AKMT2AL3MBTL1MTTP | |
| SCHEMBL12931693 | 0.71 | KMT2A (0.85) | NPC1RAB9AKMT2AL3MBTL1HPGD | |
| SCHEMBL11338718 | 0.69 | SDCBP (0.61) | KMT2AL3MBTL1HPGDTSHRMEN1 | |
| SCHEMBL11338720 | 0.69 | SDCBP (0.61) | KMT2AL3MBTL1HPGDTSHRMEN1 | |
| SCHEMBL12931717 | 0.67 | L3MBTL1 (0.56) | NPC1RAB9AKMT2AL3MBTL1TSHR | |
| SCHEMBL2751329 | 0.66 | KMT2A (0.97) | NPC1RAB9AKMT2AL3MBTL1HPGD | |
| SCHEMBL12931704 | 0.66 | KMT2A (0.91) | NPC1RAB9AKMT2AL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | claimed |
| EP-1578725-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004056777-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | MTTP, CETP, APOB | NPC1 27/4885RAB9A 3807/4885KMT2A 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.